期刊： CANCER GENE THERAPY, 2022; 29 (1)
microRNAs (miRNAs) have been revealed to participate in some oral cancers and are proved to be effective. In the present study, we tried to explore th......
期刊： CANCER GENE THERAPY, 2022; 29 (2)
Major histocompatibility complex class II (MHC II) is important for the adaptive immune response because MHC II presents processed antigens to a clust......
期刊： CANCER GENE THERAPY, 2022; 29 (5)
Overexpression of O-6-methylguanine DNA methyltransferase (MGMT) contributes to resistance to chemo-radiation therapy (CRT) in brain tumors. We previo......
期刊： CANCER GENE THERAPY, 2022; 29 (6)
CDK4/6 inhibitors significantly prolong progression-free survival in patients with advanced hormone receptor-positive (HR+) HER2-negative breast cance......
期刊： CANCER GENE THERAPY, 2022; 29 (7)
Lung carcinoma is the main reason for cancer-associated deaths in the world. In a previous study, FCH domain only 1 (FCHo1) which is managed by protei......
期刊： CANCER GENE THERAPY, 2022; 29 (1)
Significantly high-expressed circFLNA has been found in various cancer cell lines, but not in lung cancer. Therefore, this study aimed to explore the ......
期刊： CANCER GENE THERAPY, 2022; 29 (3-4)
Long non-coding RNAs (lncRNAs) were recently recognized to vitally function in a variety of cancer cellular events, including epithelial-mesenchymal t......
期刊： CANCER GENE THERAPY, 2022; 29 (6)
Immunotherapeutic strategies that combine oncolytic virus (OV) and immune checkpoint inhibitors have the potential to overcome treatment resistance in......
期刊： CANCER GENE THERAPY, 2022; 29 (7)
Engineered T-cell therapies have proven to be successful in cancer and their clinical effectiveness is directly correlated with the infused T-cell dif......
期刊： CANCER GENE THERAPY, 2022; 29 (8-9)
DNA methylation, a major biological process regulating the transcription, contributes to the pathophysiology of hematologic malignancies, and hypometh......
期刊： CANCER GENE THERAPY, 2022; 29 (6)
Multikinase inhibitors, such as sorafenib, are used for the treatment of advanced carcinomas but the response shows limited efficacy or varies a lot w......
期刊： CANCER GENE THERAPY, 2022; 29 (7)
Aberrant Notch signaling is implicated in breast cancer progression, and recent studies have demonstrated links between the Notch pathway components N......
期刊： CANCER GENE THERAPY, 2022; 29 (8-9)
Autophagy is the predominant self-eating catabolic pathway activated in response to nutrient starvation and hypoxia within the microenvironment of var......
期刊： CANCER GENE THERAPY, 2022; 29 (10)
One of the greatest challenges in the treatment of cancer is tumor heterogeneity which results in differential responses to chemotherapy and drugs tha......
期刊： CANCER GENE THERAPY, 2022; 29 (11)
Drug resistance is a key factor in the treatment failure of acute myeloid leukemia (AML). Nuclear factor E2-related factor 2 (Nrf2) plays a crucial ro......
